

Appendix 1 Search strategies [posted as supplied by author]

1. Medline (Ovid) (Search date: February 18, 2017)

- 1 glucagon like peptide*.ti,ab.
- 2 Receptors, Glucagon/ag [Agonists]
- 3 exenatide.af.
- 4 liraglutide.af.
- 5 albiglutide.af.
- 6 taspoglutide.af.
- 7 lixisenatide.af.
- 8 dulaglutide.af.
- 9 semaglutide.af.
- 10 ZP10A peptide*.af.
- 11 GLP 1 Receptor Agonist*.af.
- 12 GLP 1 RA*.af.
- 13 GLP 1RA*.af.
- 14 dipeptidyl peptidase IV inhibit*.af.
- 15 Dipeptidyl Peptidase 4 Inhibit*.af.
- 16 DPP 4 inhibit*.af.
- 17 DPP4 inhibit*.af.
- 18 DPP4i.af.
- 19 DPP IV inhibit*.af.
- 20 DPPIV inhibit*.af.
- 21 alogliptin.af.
- 22 gemigliptin.af.
- 23 "LC15 0444".af.
- 24 linagliptin.af.
- 25 saxagliptin.af.
- 26 sitagliptin.af.
- 27 vildagliptin.af.
- 28 dutogliptin.af.
- 29 teneligliptin.af.
- 30 anagliptin.af.
- 31 evogliptin.af.
- 32 DA-1229.af.
- 33 retagliptin.af.
- 34 omarigliptin.af.
- 35 gliptin*.af.
- 36 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 32 or 33 or 34 or 35
- 37 (clinical trial or controlled clinical trial or randomized controlled trial).pt.
- 38 clinical trials as topic/ or controlled clinical trials as topic/ or randomized controlled trials as topic/
- 39 random*.ti,ab.

40 clinical trial*.ti,ab.
41 controlled trial*.ti,ab.
42 case-control studies/
43 retrospective studies/
44 cohort studies/
45 longitudinal studies/
46 follow-up studies/
47 prospective studies/
48 cohort.ti,ab.
49 longitudinal.ti,ab.
50 follow up.ti,ab.
51 followup.ti,ab.
52 prospective*.ti,ab.
53 retrospective*.ti,ab.
54 nonrandom*.ti,ab.
55 comparison group*.ti,ab.
56 control group*.ti,ab.
57 database*.ti,ab.
58 population*.ti,ab.
59 registries/
60 registry.ti,ab.
61 registries.ti,ab.
62 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or
53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61
63 36 and 62
64 limit 63 to humans
65 limit 63 to animals
66 65 not 64
67 63 not 66
68 meta analysis.pt.
69 Meta-Analysis as Topic/
70 meta analy*.ti.
71 metaanaly*.ti.
72 68 or 69 or 70 or 71
73 36 and 72
74 limit 73 to humans
75 limit 73 to animals
76 75 not 74
77 73 not 76
78 67 not 77
79 remove duplicates from 78

2. Embase (Ovid) (Search date: February 18, 2017)

1 exp glucagon like peptide/

2 exp glucagon like peptide 1/
3 glp-1 receptor agonists.mp.
4 glucagon like peptide 1 receptor agonists.mp.
5 exp receptors, glucagon/
6 exp exenatide/
7 exp liraglutide/
8 exp albiglutide/
9 exp taspoglutide/
10 exp lixisenatide/
11 exp dulaglutide/
12 exp semaglutide/
13 zp10a peptide.mp.
14 zp10a peptide 1.mp.
15 glp 1 ra.mp.
16 dipeptidyl peptidase iv inhibit.mp.
17 exp dipeptidyl peptidase IV inhibitor/
18 exp dipeptidyl peptidase IV inhibitor/
19 dpp 4 inhibitor.mp.
20 dpp4i.mp.
21 dpp iv inhibitor.mp.
22 dppiv inhibitor.mp.
23 exp alogliptin/
24 exp gemigliptin/
25 "lc15 0444".mp.
26 exp linagliptin/
27 exp saxagliptin/
28 exp sitagliptin/
29 exp vildagliptin/
30 exp dutogliptin/
31 exp teneligliptin/
32 exp anagliptin/
33 exp evogliptin/
34 DA-1229.mp
35 retagliptin.mp
36 omarigliptin.mp
37 gliptin.mp.
38 exp clinical trial/ or exp controlled clinical trial/ or exp randomized controlled trial/
39 random*.mp.
40 exp case control study/
41 exp retrospective study/
42 exp cohort analysis/
43 exp longitudinal study/
44 exp follow up/
45 nonrandom.mp.

46 exp prospective study/
47 comparison group.mp.
48 exp control group/
49 database*.mp.
50 exp register/
51 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or
19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or
36 or 37
52 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50
53 51 and 52
54 limit 53 to human
55 limit 53 to animals
56 55 not 54
57 53 not 56

3. Cochrane Central Register of Controlled Trials (Ovid) (Search date: February 18, 2017)

1 glucagon like peptide.mp. or exp Glucagon-Like Peptides/
2 exp Glucagon-Like Peptide 1/ or Glucagon-Like Peptide 1.mp.
3 Receptors, Glucagon/ag [Agonists]
4 exenatide.af.
5 albiglutide.af.
6 taspoglutide.af.
7 lixisenatide.af.
8 dulaglutide.af.
9 liraglutide.af.
10 semaglutide
11 ZP10A peptide*.af.
12 GLP 1 Receptor Agonist*.af.
13 GLP 1 RA*.af.
14 GLP 1RA*.af.
15 dipeptidyl peptidase IV inhibit*.af.
16 Dipeptidyl Peptidase 4 Inhibit*.af.
17 DPP 4 inhibit*.af.
18 DPP4 inhibit*.af.
19 DPP4i.af.
20 DPP IV inhibit*.af.
21 DPPIV inhibit*.af.
22 alogliptin.af.
23 gemigliptin.af.
24 "LC15 0444".af.
25 linagliptin.af.
26 saxagliptin.af.
27 sitagliptin.af.

28 vildagliptin.af.
29 dutogliptin.af.
30 teneligliptin.af.
31 anagliptin.af
32 evogliptin.af
33 DA-1229.af
34 retagliptin.af
35 omarigliptin.af
36 gliptin*.af.
37 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or
19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or
36

4. ClinicalTrials.gov (Search date: February 18, 2017)

exenatide OR liraglutide OR albiglutide OR taspoglutide OR lixisenatide OR dulaglutide OR
semaglutide OR sitagliptin OR vildagliptin OR saxagliptin OR linagliptin OR alogliptin OR
dutogliptin OR gemigliptin OR teneligliptin OR anagliptin OR evogliptin OR retagliptin OR
omarigliptin | Studies With Results

** When searching ClinicalTrials.gov, we did not use the general terms, such as “glucagon
like peptide-1” and “dipeptidyl peptidase-4”, as this registry is designed so that one can
capture relevant trials using generic drug names directly. We did not limit the search to
completed studies, because we also included “terminated” studies with results.